June 2020, Drugs Monitor, Page 3

(08 June 2020) Tocilizumab- increased survival (p value < 0.001) statistically associated with early dosing

June 8, 2020

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 https://doi.org/10.1101/2020.06.05.20122622 This was a multi-center study with data collected by chart review both retrospectively and concurrently. Early dosing was defined as a tocilizumab dose administered prior to or… Continue reading "(08 June 2020) Tocilizumab- increased survival (p value < 0.001) statistically associated with early dosing"

(06 June 2020) Tocilizumab- reduced lethality rate at 30 but not at 14-days

June 6, 2020

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial https://doi.org/10.1101/2020.06.01.20119149 301 and 920 cases were available for intention-to-treat (ITT) analysis in phase 2 and validation cohorts (Registration. EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)). Due to delayed drug availability, 60% of… Continue reading "(06 June 2020) Tocilizumab- reduced lethality rate at 30 but not at 14-days"

(05 June 2020) Tocilizumab- less ICU admissions (10.3% vs. 27.6%, P= 0.005) in Tocilizumab group

June 6, 2020

Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection https://doi.org/10.1101/2020.06.05.20113738 In a retrospective study ,77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P=… Continue reading "(05 June 2020) Tocilizumab- less ICU admissions (10.3% vs. 27.6%, P= 0.005) in Tocilizumab group"

(5 June 2020) Tocilizumab-45% reduction in the hazard of death, despite twice the frequency of superinfection

June 6, 2020

Tocilizumab for treatment of mechanically ventilated patients with COVID-19 https://www.medrxiv.org/content/10.1101/2020.05.29.20117358v1.full.pdf In this observational cohort study, 154 patients were included, of whom 78 received tocilizumab and 76 did not. Median follow-up was 47 days (range 28-67). In IPTW-adjusted models, tocilizumab was… Continue reading "(5 June 2020) Tocilizumab-45% reduction in the hazard of death, despite twice the frequency of superinfection"

(03 June 2020) Hydroxychloroquine- no significant benefit in postexposure prophylaxis

June 4, 2020

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?query=featured_home This is a randomized, double-blind, placebo-controlled trial (NCT04308668. opens in new tab)across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. Within 4 days after exposure,… Continue reading "(03 June 2020) Hydroxychloroquine- no significant benefit in postexposure prophylaxis"

(2 June 2020) Tocilizumab- 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment

June 3, 2020

Efficacy and safety of tocilizumab in severe COVID-19 patients: a singlecentre retrospective cohort study https://www.ejinme.com/article/S0953-6205(20)30199-0/fulltext?rss=yes 65 severe COVID-19 patients were included in a retrospective study. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental… Continue reading "(2 June 2020) Tocilizumab- 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment"

(01 June 2020) Favipiravir- Lower FPV serum concentrations in critically ill patients

June 2, 2020

Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19 https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12827 The serum concentration of FPV were measured using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The… Continue reading "(01 June 2020) Favipiravir- Lower FPV serum concentrations in critically ill patients"

(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group

June 1, 2020

Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1 In this randomized clinical trial (Clinical Trial Registration ID #IRCT20100228003449N28)efficacy and safety of IFN β-1a has been evaluated in patients with severe COVID-19. Forty-two… Continue reading "(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group"

(30 May 2020) Ruxolitinib- 90% patients from the ruxolitinib group showed CT improvement at D14

June 1, 2020

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial https://doi.org/10.1016/j.jaci.2020.05.019 Authors conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe COVID-19 (ChiCTR-OPN-2000029580). Forty-three patients were randomly assigned (1:1) to… Continue reading "(30 May 2020) Ruxolitinib- 90% patients from the ruxolitinib group showed CT improvement at D14"

Month: June 2020